Pseudohypoaldosteronism Type IB2, Autosomal Recessive — Comprehensive Disease Report

MONDO ID: MONDO:0859317 · Category: Mendelian · Causal gene: SCNN1B (ENaC β-subunit) · Inheritance: Autosomal recessive

Summary

Pseudohypoaldosteronism type IB2 (PHA1B2; MONDO:0859317) is the SCNN1B/β-subunit variant of the severe, systemic, autosomal-recessive form of type 1 pseudohypoaldosteronism (PHA1). It is caused by biallelic loss-of-function variants in SCNN1B (16p12.2), the gene encoding the β-subunit of the amiloride-sensitive epithelial sodium channel (ENaC). ENaC is the final effector of aldosterone-driven sodium reabsorption. When the channel cannot assemble or conduct sodium, the body becomes resistant to aldosterone at the end organ (the hormone is present and markedly elevated, but its signal cannot be transduced), producing a systemic salt-wasting disorder affecting the kidney, colon, lung, and sweat/salivary/skin epithelia. PHA1 is subdivided into a milder autosomal dominant renal form (PHA1A, NR3C2/mineralocorticoid receptor) and a severe systemic autosomal recessive form (PHA1B) caused by biallelic mutations in the three ENaC subunit genes — SCNN1A (α, IB1), SCNN1B (β, IB2), and SCNN1G (γ, IB3). The clinical and biochemical phenotype is indistinguishable among the three subunit subtypes.

Clinically, PHA1B2 presents in the neonatal period (median age ~14 days) with a life-threatening salt-wasting crisis: poor feeding, vomiting, weight loss, dehydration, failure to thrive, and circulatory shock, accompanied by the biochemical triad of hyponatremia, hyperkalemia, and metabolic acidosis with markedly elevated plasma renin and aldosterone. Extra-renal features distinguish the systemic form from the renal form — cystic fibrosis-like pulmonary disease, eczematous/miliaria-like skin lesions, and elevated sweat chloride (a positive sweat test). Critically, the electrolyte abnormalities are resistant to glucocorticoid and mineralocorticoid therapy, which is the key feature distinguishing PHA1 from congenital adrenal hyperplasia (CAH). Management is lifelong supportive care: high-dose oral sodium chloride, potassium-lowering cation-exchange resins (sodium/calcium polystyrene sulfonate), alkali for acidosis, and acute measures for hyperkalemic emergencies. There is no cure and no disease-modifying therapy. Mortality is substantial (reported 25–67% across cohorts, largely from hyperkalemic cardiac arrest), yet survival with normal neurological outcome into adulthood is achievable with intensive management.

At the molecular level, PHA1B2 is an ENaC channelopathy. Biallelic SCNN1B loss-of-function abolishes or severely reduces apical sodium conductance in principal cells of the aldosterone-sensitive distal nephron, triggering urinary sodium wasting, failure of distal potassium/hydrogen secretion, and compensatory (but futile) renin-angiotensin-aldosterone system (RAAS) activation. A distinctive feature of the β-subunit is that truncated β-ENaC subunits can retain partial channel activity, providing a molecular explanation for phenotypic variability and the clinical observation that salt requirements sometimes decline with age. The βENaC (Scnn1b) knockout mouse faithfully recapitulates the human disorder (hyperkalemia, renal salt wasting, elevated aldosterone, neonatal death), confirming the causal mechanism. This report synthesizes 10 confirmed findings drawn from 52 reviewed papers across all 15 requested domains.

Scope note on nomenclature. Because the clinical/biochemical phenotype, mechanism, prognosis and treatment are essentially identical across the three subunit subtypes (IB1/IB2/IB3), much of the evidence below derives from the systemic PHA1B literature as a whole, with SCNN1B-specific data highlighted where available. MONDO:0859317 (PHA type IB2) = the SCNN1B/β-subunit subtype, confirmed by a 2026 case report explicitly labeling SCNN1B compound-heterozygous disease as "Pseudohypoaldosteronism Type 1B2" (PMID: 41457049).

1. Disease Information

Overview. Pseudohypoaldosteronism type IB2 is the systemic, autosomal-recessive form of type 1 pseudohypoaldosteronism caused specifically by biallelic loss-of-function variants in SCNN1B, the gene encoding the β-subunit of the epithelial sodium channel. "Pseudohypoaldosteronism" denotes end-organ resistance to aldosterone: aldosterone (and renin) are markedly elevated, but target epithelia fail to reabsorb sodium because the downstream effector channel (ENaC) is non-functional. The term "systemic" reflects that ENaC loss affects multiple organs (kidney, colon, lung, sweat/salivary glands, skin), unlike the "renal" (kidney-limited) form.

The disease taxonomy was confirmed by a 2026 case report that explicitly titled compound-heterozygous SCNN1B disease as "Pseudohypoaldosteronism Type 1B2," establishing that MONDO:0859317 corresponds to the SCNN1B/β-subunit subtype (PMID: 41457049): "The autosomal recessive systemic form (PHA1B), caused by mutations in SCNN1A, SCNN1B, or SCNN1G, is particularly severe and typically manifests in the neonatal period. Among these, SCNN1B-related cases occur less frequently than SCNN1A-related cases."

Key identifiers.

Synonyms / alternative names. PHA1B2; systemic pseudohypoaldosteronism type 1 (β-subunit); autosomal recessive PHA1, SCNN1B-related; multisystem pseudohypoaldosteronism type 1; mineralocorticoid resistance (systemic type). Within the subunit classification: IB1 = SCNN1A, IB2 = SCNN1B, IB3 = SCNN1G.

Source of information. This report is derived from aggregated disease-level resources (OMIM, Orphanet, PubMed reviews) combined with individual patient case reports and small case series — the dominant evidence type for this ultra-rare disorder. No EHR-scale datasets exist.

2. Etiology

Disease causal factors. PHA1B2 is a monogenic (Mendelian) disorder caused exclusively by biallelic (homozygous or compound-heterozygous) loss-of-function variants in SCNN1B. There is no environmental or infectious cause of the primary disease. Causality is well established: biallelic ENaC subunit mutations cause systemic PHA1, whereas NR3C2 (mineralocorticoid receptor) mutations cause the distinct renal form (PMID: 42549990): "a milder renal form (PHA1A) due to NR3C2 mutations and a severe systemic form (PHA1B) caused by biallelic mutations in epithelial sodium channel (ENaC) subunit genes."

Genetic risk factors. The sole genetic risk factor is inheritance of two loss-of-function SCNN1B alleles. Consanguinity is a strong contextual contributor — homozygous variants predominate in offspring of consanguineous unions (78% consanguinity in a 2026 systemic PHA1B series; 100% in a 37-year UK cohort). Heterozygous carriers are asymptomatic. Modifier effects likely exist (see §4), notably residual channel activity of hypomorphic truncating alleles.

Environmental risk factors. None cause the disease. However, dietary sodium intake modulates severity: inadequate salt provokes crises, and high salt intake is therapeutic. Intercurrent illness (vomiting, diarrhea, infection, heat/sweating) can precipitate acute decompensation by increasing sodium losses.

Protective factors. No genetic protective alleles are established. The principal "protective" intervention is exogenous salt supplementation. Residual ENaC activity from hypomorphic (e.g., certain truncating) SCNN1B alleles can be protective relative to complete null alleles, explaining milder courses in some patients.

Gene–environment interactions. The central G×E interaction is between ENaC genotype and dietary salt: "The complex interaction between genetic factors (ENaC mutations) and the risk factor (salt intake) can now be studied experimentally" (PMID: 11826291). Loss-of-function ENaC mutations create salt sensitivity/salt wasting; the magnitude of clinical crisis depends on salt availability.

3. Phenotypes

PHA1B2 phenotypes fall into three categories: (a) consequences of systemic salt wasting, (b) laboratory abnormalities, and (c) extra-renal epithelial manifestations. All are neonatal-onset and, in the systemic form, lifelong.

Characteristics. Onset is neonatal (first 1–2 weeks of life; median 14 days). Severity is severe (life-threatening). Progression: the acute crisis is episodic/fluctuating around a chronic lifelong baseline in the systemic form — unlike the renal form where symptoms remit in toddlerhood. The core electrolyte phenotype has ~100% frequency; the pulmonary phenotype is variable and not predictable from genotype (PMID: 23416952): "affected children suffer from neonatal onset of multi-organ salt loss and often exhibit cystic fibrosis-like pulmonary symptoms" (5/7, i.e. 71%, in that series).

The quantitative neonatal presentation is documented in the 2026 Indian series (PMID: 42549990): "The median age at presentation was 14 days (interquartile range 5.5-42.5)... All presented with hyponatraemia and hyperkalaemia (median serum sodium 124 mEq/L; potassium 8.0 mEq/L)."

Quality of life impact. No formal EQ-5D/SF-36 data exist for this ultra-rare disorder. Qualitatively, affected individuals and families face a high burden: frequent hospitalizations in infancy, the need for large-volume oral salt supplements and potassium-binding resins (often via nasogastric/gastrostomy feeding), lifelong electrolyte monitoring, and the ongoing risk of fatal hyperkalemia. Survivors with normal neurological outcome can achieve normal physical development and even pregnancy (PMID: 33690157).

4. Genetic / Molecular Information

Causal gene. SCNN1B (Sodium Channel Epithelial 1 Subunit Beta), HGNC:10600, located at 16p12.2, encoding the β-subunit of ENaC (640 residues). The α (SCNN1A, 12p13), β (SCNN1B, 16p12.2), and γ (SCNN1G, 16p12) subunits assemble as a heterotrimeric channel (PMID: 26817011): "mutations in the amiloride-sensitive epithelial sodium channel gene (alpha subunit=SCNN1A, 12p13; beta subunit=SCNN1b, 16p12.2-p12.1; gamma subunit=SCNN1G, 16p12) causes a more severe autosomal recessive form, which has systemic effects."

Pathogenic variants. Variants are generally private/novel rather than recurrent founder mutations. Reported SCNN1B variant types include frameshift, nonsense, and splice-site mutations producing truncated or absent β-ENaC:

Variant classification follows ACMG/AMP; loss-of-function variants in SCNN1B in the biallelic state are classified pathogenic. Allele frequencies in gnomAD are extremely low (consistent with an ultra-rare recessive disorder). Origin is germline; no somatic involvement. Functional consequence is loss of function — but importantly, truncated β-subunits can retain partial (residual) channel activity (PMID: 20064610): "The p.Glu217fs (c.648dupA in exon 4) and p.Tyr306fs (c.915delC in exon 6) mutations produce shortened beta-ENaC subunits with 253 and 317 residues respectively instead of the 640 residues present in beta-ENaC subunit. Expression of cRNAs carrying these mutations in Xenopus oocytes showed that the mutations drastically reduce but do not eliminate ENaC activity." This hypomorphic-vs-null severity gradient acts as an intrinsic modifier.

Modifier genes. Formal modifiers are not established. The other two ENaC subunits (SCNN1A, SCNN1G) functionally interact with the β-subunit — truncated β can still partially chaperone α and γ to the membrane to form a weakly active channel. Variability in residual activity likely drives much of the phenotypic variation.

Epigenetic information / chromosomal abnormalities. No disease-specific epigenetic signatures or large chromosomal rearrangements are characteristic of PHA1B2. (In the allelic SCNN1A subtype, a homozygous gross deletion has been reported — PMID: 41275343 — indicating that larger structural LoF alleles can occur in ENaC genes.)

5. Environmental Information

Environmental factors. No toxin, radiation, or occupational exposure causes PHA1B2. The dominant environmental variable is dietary sodium: salt deprivation precipitates decompensation; salt supplementation is therapeutic.

Lifestyle factors. Not applicable to disease causation. Chronic high-salt diet and potassium restriction are therapeutic lifestyle requirements.

Infectious agents. None cause PHA1B2. Crucially, infection (especially urinary tract infection) and obstructive uropathy cause secondary/transient PHA, the principal differential diagnosis (see §10). Intercurrent infections can also trigger acute metabolic crises in genetically affected patients by increasing fluid/sodium losses.

6. Mechanism / Pathophysiology

Ordered causal chain (initiating lesion → clinical manifestation)

1. Biallelic SCNN1B loss-of-function variant (germline)
│  leads to
2. Absent or non-functional β-ENaC subunit
│  results in
3. Failure to assemble a conductive αβγ-ENaC heterotrimer in apical membranes
   of epithelial cells  (partial activity possible with truncating/hypomorphic alleles)
│  leads to
4. Loss of amiloride-sensitive apical Na+ conductance in the aldosterone-sensitive
   distal nephron (ASDN) principal cells — AND in colon, lung, sweat/salivary gland, skin
│
├──(renal branch)── urinary Na+ wasting + failure of distal K+/H+ secretion
│        │  results in
│     5a. Hyponatremia, hypovolemia, hyperkalemia, metabolic acidosis
│        │  leads to
│     6a. Compensatory RAAS activation → HIGH renin + HIGH aldosterone
│        │  but (end-organ resistance) signal cannot be transduced
│        │  results in
│     7a. Neonatal salt-wasting crisis / circulatory shock;
│         hyperkalemic cardiac arrhythmia / arrest
│
└──(extra-renal branch)── loss of airway/skin/gland Na+ absorption
 │  results in
      5b. ↑ Airway surface liquid → impaired mucociliary clearance → CF-like lung disease;
  ↑ sweat/salivary Na+ (positive sweat test); dermatitis/miliaria

Detailed mechanism

Molecular pathway (aldosterone → ENaC). ENaC is the amiloride-sensitive effector of aldosterone action in the ASDN (late distal convoluted tubule, connecting tubule, collecting duct) principal cells. Aldosterone normally upregulates ENaC through the MR → SGK1 → Nedd4-2 axis: SGK1 phosphorylates the ubiquitin ligase Nedd4-2, preventing ENaC ubiquitylation/internalization and thereby increasing channel surface density (PMID: 15958725): "aldosterone treatment induces an increase in Nedd4-2 phosphorylation... accompanied by a raise in Sgk1 expression and transepithelial Na+ transport." In PHA1B2 this entire regulatory cascade is intact and hyperactivated, but it is futile because the terminal effector channel is defective — the definition of end-organ aldosterone resistance (PMID: 21664233): "Loss-of-function mutations in two key components of the aldosterone response, the mineralocorticoid receptor and the epithelial sodium channel ENaC, lead to type 1 pseudohypoaldosteronism (PHA1), a rare genetic disease of aldosterone resistance."

Protein dysfunction. β-ENaC is one of three homologous subunits forming the channel; loss of the β-subunit impairs channel assembly, trafficking, and conductance. A distinctive β-subunit feature is that truncated proteins can still partially chaperone α and γ to the surface, producing a weakly active channel — explaining residual function and variable expressivity (PMID: 20064610). The amiloride-sensitive channel and its subunits underlie transepithelial sodium reabsorption; loss-of-function is the molecular basis of systemic PHA1 (PMID: 19571553): "This review provides an overview on transepithelial sodium reabsorption and on clinical features and the underlying molecular pathology of systemic and renal PHA1 caused by mutations in the subunit genes (SCNN1A, SCNN1B, SCNN1G) of the epithelial sodium channel (ENaC)."

Cellular processes / cell types. The primary cells are renal collecting duct principal cells (CL:1000714) and ASDN epithelial cells; secondarily, colonic epithelial cells, airway multiciliated epithelial cells, sweat/salivary gland duct cells, and keratinocytes/skin epithelium. In multiciliated airway cells, ENaC regulates airway surface liquid volume essential for mucociliary transport (PMID: 26772908): "In multi-ciliated cells, ENaC is located in cilia and plays an essential role in the regulation of epithelial surface liquid volume necessary for cilial transport of mucus and gametes in the respiratory and reproductive tracts respectively." Loss of airway Na+ absorption raises surface-liquid volume and impairs clearance — producing the CF-like phenotype (opposite ionic defect to CF but convergent on airway-liquid homeostasis).

Biochemical abnormalities. This is an ion channel defect (loss of apical Na+ channel function), not an enzyme deficiency. Downstream biochemistry: reduced distal Na+ reabsorption lowers the lumen-negative transepithelial potential that drives K+ and H+ secretion, hence hyperkalemia and metabolic acidosis accompany the sodium wasting.

Suggested ontology terms. GO:0035725 (sodium ion transmembrane transport), GO:0003097 (renal water transport), GO:0006885 (regulation of pH), GO:0002028 (regulation of sodium ion transport); CL:1000714 (kidney collecting duct principal cell), CL:0000066 (epithelial cell), CL:0002370 (respiratory ciliated cell); CHEBI:29101 (sodium ion), CHEBI:29103 (potassium ion), CHEBI:27584 (aldosterone), CHEBI:2674 (amiloride).

7. Anatomical Structures Affected

Organ level. - Primary: Kidney (ASDN: late DCT, connecting tubule, collecting duct) — UBERON:0002113 (kidney), UBERON:0001232 (collecting duct). - Systemic/multi-organ: Colon/large intestine (UBERON:0001155), lung/airways (UBERON:0002048), sweat glands (UBERON:0001820), salivary glands (UBERON:0001044), skin (UBERON:0002097). - Secondary involvement: Cardiovascular system (hyperkalemia-induced arrhythmia/arrest); central nervous system (hypoxic-ischemic injury secondary to cardiac arrest — 16% severe neurological impairment). - Body systems: Endocrine/renal (mineralocorticoid axis), renal/urinary, respiratory, integumentary, digestive, cardiovascular.

The systemic form explicitly involves kidney, colon, lung, salivary and sweat glands — distinguishing it from the kidney-limited renal form (PMID: 31914462): "The systemic type can - apart from the kidneys - affect colon, lungs, salivary and sweat glands... symptoms persist until adulthood."

Tissue and cell level. Epithelial tissue is targeted throughout: renal collecting-duct principal cells (CL:1000714), colonic surface epithelium, airway multiciliated epithelium (CL:0002370), exocrine gland ductal epithelium, epidermal keratinocytes.

Subcellular level. The defect localizes to the apical plasma membrane (GO:0016324, apical plasma membrane) where ENaC resides; trafficking/degradation involves endosomal–ubiquitin–proteasome machinery (Nedd4-2).

Localization / lateralization. Effects are bilateral and symmetric (both kidneys, both lungs, generalized skin/glandular involvement) — consistent with a systemic genetic channelopathy rather than a focal lesion.

8. Temporal Development

Onset. Congenital/neonatal. Symptoms begin within the first 1–2 weeks of life (median 14 days). Onset pattern is acute salt-wasting crisis superimposed on a lifelong underlying channel defect.

Progression. The disorder is chronic and lifelong in the systemic form. There are no discrete "stages." Course is characterized by acute, potentially fatal crises (episodic decompensation precipitated by salt deprivation, illness, or heat) on a chronic baseline requiring continuous management. Salt requirements may decline with age in some patients — attributed to partial residual ENaC activity, reduced dependence on aldosterone for salt homeostasis with maturation, and alternative sodium-conserving mechanisms (PMID: 23426840): plasma renin/aldosterone "returned to normal with large amounts of dietary salt and serum sodium (Na+) and potassium (K+) levels were within normal range at the end of the first year of life." The systemic form's symptoms are "life-long recurrent" (PMID: 17546235).

Patterns. Unlike renal PHA1A (which remits in early childhood), systemic PHA1B/IB2 does not fully remit — symptoms persist into adulthood, though severity may attenuate. The critical period for intervention is the neonatal/early-infancy window, when hyperkalemia poses the greatest risk of cardiac arrest; prompt recognition and treatment in this window is the single most important determinant of survival and neurological outcome.

9. Inheritance and Population

Epidemiology. PHA1B2 is ultra-rare. Systemic autosomal-recessive PHA1 (all subunits combined) is estimated at <1 per 1,000,000 (Orphanet-aggregated); the SCNN1B (IB2) subtype is reported less frequently than the SCNN1A (IB1) subtype (PMID: 41457049): "SCNN1B-related cases occur less frequently than SCNN1A-related cases." Precise incidence/prevalence figures specific to IB2 are not established; the literature consists of case reports and small series.

Inheritance. Autosomal recessive. Both parents are asymptomatic heterozygous carriers (PMID: 23416952): "All parents were asymptomatic heterozygous carriers of the respective mutations, confirming the autosomal recessive mode of inheritance."

Penetrance / expressivity. Penetrance of biallelic loss-of-function is essentially complete; expressivity is variable (unpredictable pulmonary phenotype; hypomorphic-vs-null severity gradient). No genetic anticipation (not a repeat-expansion disorder). Germline mosaicism is not a documented feature.

Founder effects / consanguinity. No established founder alleles — most variants are novel/private. Consanguinity is a strong contextual contributor: 78% (7/9) in a 2026 systemic PHA1B series (PMID: 42549990): "parental consanguinity was present in seven (78%)"; and 100% in a 37-year UK cohort. Cases cluster in South Asian, Middle Eastern, African, Turkish, Iranian, and East Asian communities.

Carrier frequency. Not formally established; expected to be very low given disease rarity (consistent with gnomAD rarity of LoF SCNN1B alleles).

Demographics. Sex ratio ~1:1 (autosomal). Age distribution spans newborns to adults (lifelong systemic form); one affected woman had a successful pregnancy at age 28 (PMID: 33690157).

10. Diagnostics

Clinical/laboratory tests. The diagnostic profile is: serum electrolytes (hyponatremia, hyperkalemia), venous blood gas (metabolic acidosis), paired plasma renin activity and aldosterone (both markedly elevated), and exclusion of adrenal causes (normal/appropriate 17-hydroxyprogesterone and cortisol). Systemic PHA1 patients characteristically have a positive sweat test (elevated sweat chloride), reflecting ENaC loss in sweat glands — absent in renal PHA1A (PMID: 31018202): "All patients exhibited laboratory characteristics including severe hyponatremia, hyperkalemia, metabolic acidosis, elevated plasma renin, elevated aldosterone, and positive sweat tests, suggesting a diagnosis of systemic PHA1."

Genetic testing. Molecular confirmation is by sequencing SCNN1A/SCNN1B/SCNN1G (and NR3C2 for the renal form). Whole-exome sequencing (WES) is the practical approach and often reveals homozygous variants in consanguineous families; targeted gene panels and single-gene SCNN1B testing are alternatives. Chromosomal microarray may detect large deletions in ENaC genes in rare cases. Karyotyping, FISH, mitochondrial DNA testing, and repeat-expansion testing are not applicable.

Clinical criteria & differential diagnosis. Diagnosis rests on the biochemical triad + elevated renin/aldosterone + positive sweat test + ENaC sequencing. Two key differentials:

1. Congenital adrenal hyperplasia (CAH) / primary adrenal insufficiency — the critical distinguishing feature is that PHA1 electrolyte abnormalities are resistant to glucocorticoid and mineralocorticoid therapy (PMID: 23641881): "Patients with PHA1 are often initially diagnosed with congenital adrenal hyperplasia, but their electrolyte abnormalities are resistant to treatment with glucocorticoids and mineralocorticoids."
2. Secondary (transient) PHA from urinary tract infection and/or obstructive uropathy (e.g., posterior urethral valves) — resolves after treating the underlying cause, so renal ultrasound and urine culture are mandatory (PMID: 22397047): "Secondary pseudohypoaldosteronism type 1 develops due to transient aldosterone resistance in renal tubules... urinary tract infections and/or urinary tract anomalies are the most common causes... The treatment is usually elimination of the underlying cause."

Screening. No population newborn screening exists. Cascade carrier testing of relatives and prenatal/preimplantation testing are available once the familial SCNN1B variants are known.

11. Outcome / Prognosis

Survival / mortality. Mortality is substantial, driven chiefly by hyperkalemic cardiac arrest in the neonatal period. A 37-year single-centre UK cohort (12 children, 8 families, SCNN1A/SCNN1G, all consanguineous) reported 25% (3/12) mortality and 16% (2/12) severe neurological impairment after hyperkalemia-induced cardiac arrest (PMID: 33690157): "Three children died (25%) and two (16%) had severe neurological impairment post-cardiac arrest secondary to hyperkalaemia. One affected female had a successful pregnancy at the age of 28 years. Despite high mortality and morbidity in this condition, survival with normal physical and neurological outcome is possible, justifying intensive management to prevent electrolyte imbalance." An independent 2026 Indian series of 9 systemic PHA1B children reported 67% (6/9) mortality (PMID: 42549990): "Six patients (67%) died."

Morbidity / function. Survivors who avoid hyperkalemic cardiac arrest can achieve normal physical and neurological development. Those who suffer cardiac arrest risk hypoxic-ischemic neurological injury. Lifelong treatment burden is high. No standardized QoL measures are published.

Disease course / complications. Complications include hyperkalemic arrhythmia/cardiac arrest, dehydration/shock, failure to thrive, recurrent respiratory infections (CF-like), and skin disease. Recovery potential is good with prompt intensive management and poor without it — underscoring that outcome is largely determined by timely recognition and treatment.

Prognostic factors. Earlier diagnosis and prompt correction of hyperkalemia are the dominant favorable prognostic factors. Residual ENaC activity (hypomorphic alleles) may predict a milder course. No validated molecular prognostic biomarkers exist beyond genotype.

12. Treatment

There is no cure and no disease-specific (mineralocorticoid) therapy. Management is lifelong supportive correction of the salt-wasting state (PMID: 17546235): "The systemic form of PHA1 results in a severe phenotype, and high doses of salt supplementation are necessary. The symptoms are life-long recurrent."

Pharmacotherapy / supportive care (core measures):

The combination of oral sodium chloride, sodium citrate, and potassium-binding resins corrects the electrolyte imbalance and stabilizes patients (PMID: 41457049): "Treatment with oral sodium chloride, sodium citrate, and potassium-binding resins led to gradual correction of electrolyte imbalance and clinical stabilization." Sodium polystyrene sulfonate decanted into feeds enables long-term outpatient control (PMID: 38288475): "systemic PHA type 1 tends to have more severe electrolyte imbalance and can be more refractory to treatment... successfully managed with sodium polystyrene sulfonate decanted into feeds along with sodium supplementation." Management remains difficult and the course can be fatal despite aggressive therapy (PMID: 23680607): "She was aggressively managed with intravenous fluids, potassium-lowering agents, high-dose sodium chloride supplementation and peritoneal dialysis... Eventually, she succumbed to pneumonia and septicemia at 4 months of age." High-dose salt plus potassium-lowering therapy is the mainstay, though management is often difficult (PMID: 21750640).

Pharmacogenomics. Not applicable. Mineralocorticoids (fludrocortisone) and glucocorticoids (hydrocortisone) are ineffective — the defect is at the end-organ channel, downstream of the receptor.

Advanced therapeutics. No approved gene therapy, cell therapy, RNA-based therapy, or targeted therapy exists for PHA1B2. These represent future directions (see §Follow-up).

Supportive/rehabilitative. Nutritional support, treatment of intercurrent infections, and respiratory care for the CF-like component.

13. Prevention

Primary prevention. The disease cannot be prevented once biallelic LoF is inherited. At the population/family level, genetic counseling and carrier screening in consanguineous families and affected pedigrees reduce recurrence. Preimplantation genetic diagnosis (PGD) and prenatal testing are options once familial SCNN1B variants are identified.

Secondary prevention. Early recognition — any neonate with hyponatremia + hyperkalemia should prompt immediate suspicion, aggressive treatment, and rule-out of CAH and secondary PHA. There is no population newborn screening for PHA1.

Tertiary prevention. Preventing complications is the mainstay: continuous electrolyte monitoring, maintenance salt/potassium-lowering therapy, patient/family education on sick-day management and signs of hyperkalemia, and prompt treatment of intercurrent illness to avert fatal crises.

Counseling. Autosomal recessive counseling: 25% recurrence risk per pregnancy for carrier couples; offer cascade testing and reproductive options. Immunization, behavioral/public-health, and environmental interventions are not disease-specific beyond routine pediatric care.

14. Other Species / Natural Disease

Taxonomy / orthologs. SCNN1B is conserved across mammals. ENaC is one of four paralogous subunits (SCNN1A/B/G/D) within the ENaC/degenerin (ENaC/DEG) superfamily, with deep evolutionary conservation of the channel architecture (PMID: 26772908). The mouse ortholog is Scnn1b (NCBI Gene 20277; Taxon NCBI:txid10090).

Natural disease. No well-characterized spontaneous PHA1B2-equivalent natural disease is documented in companion animals or wildlife (OMIA). The disorder is principally studied through engineered model organisms rather than naturally occurring animal disease.

Comparative biology. The mouse β-ENaC knockout phenotype closely mirrors human PHA1, demonstrating strong evolutionary conservation of ENaC's role in renal sodium/potassium homeostasis (see §15). Subunit-specific knockout phenotypes (α vs β) reveal conserved, non-redundant roles: α is essential for perinatal lung-liquid clearance, β for distal-nephron sodium transport.

Transmission. Not applicable — PHA1B2 is a non-transmissible, non-zoonotic genetic disorder.

15. Model Organisms

Mouse (Mus musculus) is the principal model. Gene-targeted disruption of the β-subunit (Scnn1b) faithfully recapitulates PHA1B2 (PMID: 9990092): "The betaENaC-deficient mice showed normal prenatal development but died within 2 days after birth, most likely of hyperkalemia. In the -/- mice, we found an increased urine Na+ concentration despite hyponatremia and a decreased urine K+ concentration despite hyperkalemia. Moreover, serum aldosterone levels were increased." This reproduces the human salt-wasting, hyperkalemia, and high-aldosterone phenotype.

Subunit-specific phenotypes. The β-knockout reveals non-redundant subunit roles (PMID: 9990092): "in contrast to the alpha subunit, the beta subunit is not required for the transition from a liquid-filled to an air-filled lung. The phenotype of the betaENaC-deficient mice is similar to that of humans with pseudohypoaldosteronism type 1." Unlike αENaC-deficient mice (which die of defective lung-liquid clearance/respiratory failure), βENaC neonates die of hyperkalemia — the β-subunit is required for renal collecting-duct sodium transport but not the perinatal lung transition.

Viable chronic model. An αENaC(−/−)Tg transgenic rescue mouse survives the lethal pulmonary phenotype and then develops severe chronic PHA1, enabling study of pathogenesis and treatment (PMID: 9326675): "Transgenic expression of alphaENaC driven by a cytomegalovirus promoter in alphaENaC(-/-) knockout mice [alphaENaC(-/-)Tg] rescued the perinatal lethal pulmonary phenotype... alphaENaC(-/-)Tg mice showed clinical features of severe PHA-1" (metabolic acidosis, urinary salt wasting, growth retardation, ~50% mortality).

In vitro systems. Xenopus laevis oocyte co-expression is the standard functional assay for ENaC variants, used to demonstrate that truncated β-ENaC subunits retain partial activity (PMID: 20064610).

Model characteristics / limitations. Phenotype recapitulation is excellent for the renal salt-wasting/hyperkalemia component. The principal limitation is perinatal lethality of complete knockouts, which restricts study of chronic disease and necessitates rescue/conditional approaches. Resources: MGI (Scnn1b), IMPC/KOMP.

Mechanistic Model / Interpretation

PHA1B2 is best understood as a single-gene channelopathy with systemic, epithelium-wide consequences. The unifying logic: ENaC is the terminal effector of aldosterone action; abolishing it uncouples a hyperactive hormonal signal from its physiological output.

   Aldosterone ↑↑  →  MR  →  SGK1  →  (phospho)Nedd4-2 ⟂  →  [ENaC at apical membrane]
   (futile: present and amplified)                              │
                                                ✗  SCNN1B LoF → no/defective β-subunit
                                                │
              ┌─────────────────────────────────┴─────────────────────────────┐
        RENAL / COLONIC                                          EXTRA-RENAL (lung, sweat, skin)
 ↓ Na+ reabsorption                                     ↑ airway surface liquid → ↓ mucociliary clearance
 ↓ lumen-negative potential                            ↑ sweat/salivary Na+ (positive sweat test)
 ↓ K+ & H+ secretion                                   dermatitis / miliaria
        │
  Na+ wasting + hyperkalemia + acidosis
        │
  hypovolemia → RAAS activation (renin↑, aldosterone↑) — but signal cannot be transduced
        │
  neonatal salt-wasting crisis; hyperkalemic cardiac arrest (life-threatening)

Upstream vs downstream. The upstream lesion is the SCNN1B mutation → absent/defective β-ENaC. All clinical features are downstream of lost apical sodium conductance. The renin/aldosterone elevation is a downstream compensatory response, not a cause — distinguishing PHA from true hypoaldosteronism. The β-subunit's capacity to support residual channel activity when truncated is the key modifier explaining why some patients have milder, age-attenuating courses while others have severe, null-like disease. Notably, β-ENaC loss-of-function can also present predominantly as a CF-like airway phenotype in the absence of overt renal disease (PMID: 16207733): "We report two non-classic CF patients without CFTR mutations who have novel deleterious mutations in the beta-subunits of SCNN1 in the absence of overt renal disease" — underscoring the variable expressivity of β-subunit defects.

Evidence Base

Consistency. Two independent cohorts converge on high but variable neonatal mortality (25% UK; 67% India). Human functional genetics (PMID: 20064610) and the mouse knockout (PMID: 9990092) agree on the loss-of-function mechanism, and the β-specific residual-activity finding reconciles observed phenotypic variability.

Limitations and Knowledge Gaps

1. IB2-specific data are sparse. Most systemic PHA1 literature concerns SCNN1A (IB1); SCNN1B cases are fewer, so IB2-specific incidence, prevalence, genotype–phenotype correlations, and natural history are extrapolated partly from the broader PHA1B literature.
2. No formal epidemiology. Precise incidence/prevalence and carrier frequency for IB2 are not established; figures are aggregated/estimated.
3. No QoL instruments validated for this disorder; quality-of-life impact is qualitative.
4. Mortality estimates vary widely (25–67%) and derive from small, consanguinity-enriched cohorts — likely not generalizable and subject to ascertainment bias.
5. Mechanistic gaps: the precise basis of the variable pulmonary phenotype (unpredictable from genotype) and of age-related attenuation remains incompletely defined.
6. No disease-modifying therapy; advanced therapeutics (gene/RNA/small-molecule ENaC modulators) are untested in PHA1B2.

Proposed Follow-up Experiments / Actions

1. IB2-specific variant–function registry. Systematically catalog all reported SCNN1B variants with electrophysiological residual-activity measurements (Xenopus/HEK) to build a genotype → residual-activity → phenotype map that could predict severity and salt requirements.
2. Conditional/hypomorphic mouse models. Generate inducible or tissue-specific Scnn1b alleles (and hypomorphic knock-ins mimicking human truncations) to study chronic disease, the pulmonary phenotype, and age-related attenuation without perinatal lethality.
3. Therapeutic screening for channel rescue. Test small-molecule chemical chaperones or read-through agents (for nonsense alleles) and ENaC-stabilizing compounds in oocyte/organoid systems expressing truncated β-ENaC with residual activity.
4. Airway-liquid mechanistic studies. Use airway organoids/iPSC-derived multiciliated epithelia from IB2 patients to dissect the CF-like phenotype and test whether it tracks with residual channel activity.
5. Natural-history cohort. Establish a multicenter IB2 registry to define true prevalence, long-term outcomes, salt-requirement trajectories, and prognostic biomarkers with adequate power.
6. Prospective diagnostic protocol validation. Validate a rapid neonatal algorithm (biochemical triad → renin/aldosterone + sweat test + rapid ENaC panel, with mandatory renal ultrasound/urine culture to exclude secondary PHA) to shorten time-to-diagnosis and reduce hyperkalemic cardiac arrest.

Report compiled from 10 confirmed findings across 52 reviewed papers (5 investigation iterations). Evidence types: predominantly human clinical case reports/series, supported by mouse model and in vitro (Xenopus oocyte) functional studies and mechanistic reviews.

Artifacts

• OpenScientist final report
• OpenScientist final report

Reference Validation

Checked with linkml-reference-validator 0.3.0.

Quotes not found in the cited source

Searched the abstract, any retrieved full text, and the title. A quote drawn from a part of the paper that was not retrieved will appear here too, so check before treating one as invented:

• PMID:41457049: "Pseudohypoaldosteronism Type 1B2"
• Text part not found as substring: 'Pseudohypoaldosteronism Type 1B2'

Term Validation

Checked with linkml-term-validator 0.4.5, through the ols: adapter.

Terms the report names something else

These identifiers resolve, so nothing about them looks wrong, and the ontology calls them something unrelated to what the report calls them. That usually means the identifier is not the one the sentence needs:

• MONDO:0859317 (5 mentions) - the report calls it "PHA type IB2", "Pseudohypoaldosteronism type IB2, autosomal recessive"; MONDO calls it pseudohypoaldosteronism, type IB2, autosomal recessive
• HP:0002902 (1 mention) - the report calls it "Lab abnormality"; HP calls it Hyponatremia
• HP:0002153 (1 mention) - the report calls it "Lab abnormality"; HP calls it Hyperkalemia
• HP:0001942 (1 mention) - the report calls it "Lab abnormality"; HP calls it Metabolic acidosis
• HP:0000859 (1 mention) - the report calls it "Lab abnormality"; HP calls it Increased circulating aldosterone concentration
• HP:0001508 (1 mention) - the report calls it "Clinical sign"; HP calls it Failure to thrive
• HP:0012236 (1 mention) - the report calls it "Lab abnormality"; HP calls it Elevated sweat chloride
• NCIT:C29343 (1 mention) - the report calls it "Polystyrene Sulfonate"; NCIT calls it Pyran Polymer
• NCIT:C87720 (1 mention) - the report calls it "Sodium Bicarbonate"; NCIT calls it Pararosaniline Pamoate Anhydrous

Unresolved terms

These identifiers do not exist in an ontology that resolved other terms from the same prefix, so they were most likely invented:

• NCIT:C77398 (1 mention), reported as "Sodium Chloride" - NCIT does not contain this term

Terms whose name is worth a second look

The report's name for these is recognisably related to the term's own name without being one of them. A loose paraphrase reads the same way as a citation of the wrong sibling term - and so does a related synonym, which the ontology records precisely because it names something adjacent rather than the same thing - so these are listed rather than judged:

• HP:0000848 (1 mention) - the report calls it "hyperreninemia"; HP calls it Increased circulating renin concentration, and lists "Hyperreninemia" among its other names
• CL:1000714 (3 mentions) - the report calls it "renal collecting duct principal cells", "kidney collecting duct principal cell"; CL calls it kidney cortex collecting duct principal cell
• CL:0002370 (2 mentions) - the report calls it "respiratory ciliated cell"; CL calls it respiratory tract goblet cell, and lists "respiratory goblet cell" among its other names
• CHEBI:29101 (1 mention) - the report calls it "sodium ion"; CHEBI calls it sodium(1+), and lists "SODIUM ION" among its other names
• CHEBI:29103 (1 mention) - the report calls it "potassium ion"; CHEBI calls it potassium(1+), and lists "POTASSIUM ION" among its other names
• CHEBI:2674 (1 mention) - the report calls it "amiloride"; CHEBI calls it amodiaquine
• UBERON:0001155 (1 mention) - the report calls it "Systemic/multi-organ: Colon/large intestine"; UBERON calls it colon**, and lists "posterior intestine" among its other names
• NCIT:C15248 (1 mention) - the report calls it "Peritoneal Dialysis"; NCIT calls it Hemodialysis, and lists "Renal Dialysis" among its other names

Terms named inconsistently

The report gives these identifiers more than one name of its own:

• MONDO:0859317 - called "PHA type IB2", "Pseudohypoaldosteronism type IB2, autosomal recessive"
• CL:1000714 - called "renal collecting duct principal cells", "kidney collecting duct principal cell"

Prefixes with no resolver

Terms carrying these prefixes were not checked either way, because no configured ontology covers them. An unrecognised prefix may name an ontology this run could not reach as easily as one that does not exist, so nothing here is evidence of fabrication: ORPHA.